LEXICON PHARMACEUTICALS, INC.
LXRXNext catalyst
Sotagliflozin
Type 2 Diabetes Mellitus
Get an email about LXRX's next catalysts
Track LEXICON PHARMACEUTICALS (LXRX) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
Plus 1 more upcoming event in our data (Phase 2 readout).See the timeline
2 upcoming, 1 past
Sotagliflozin Phase 3 Est. Readout (SONATA-HCM)
Estimated primary completion for Sotagliflozin trial (NCT06481891) in Obstructive Cardiomyopathy, Hypertrophic. Topline data typically follows completion by weeks to months.
SourceSotagliflozin Phase 2 Est. Readout (SOPHIST)
Estimated primary completion for Sotagliflozin trial (NCT06435156) in Type 1 Diabetes. Topline data typically follows completion by weeks to months.
SourceMarket Overview
Stock performance and key metrics
Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company developing treatments for human disease. The company was founded in 1995 in The Woodlands, Texas under the name Lexicon Genetics, Incorporated by co-founders Professor Allan Bradley, FRS and Professor Bradley's postdoctoral fellow Arthur T Sands. The company has used its mouse gene knockout technology and in vivo screening capabilities to study nearly 5,000 genes in its Genome5000 program and has identified over 100 potential therapeutic targets. Lexicon has advanced multiple drug candidates into human clinical trials and has a broad and diverse pipeline of drug targets behind its clinical programs. Lexicon is pursuing drug targets in five therapeutic areas including oncology, gastroenterology, immunology, metabolism, and ophthalmology.
WebsiteTelotristat etiprate
Carcinoid Syndrome
Oral Antidiabetes Drugs (OADs)
Type 2 Diabetes Mellitus
Insulin glargine (HOE901)
Type 2 Diabetes Mellitus
Sotagliflozin
Type 2 Diabetes Mellitus
Sulfonylurea
Type 2 Diabetes Mellitus
Sotagliflozin (SAR439954)
Type 2 Diabetes Mellitus
Glimepiride
Type 2 Diabetes Mellitus
LX1031 High Dose
Irritable Bowel Syndrome
LX9211 (blinded)
Diabetic Peripheral Neuropathic Pain
Volagidemab
Type 1 Diabetes
Telotristat Ethyl
Locally Advanced Unresectable Pancreatic Adenocarcinoma
LX3305 high dose
Rheumatoid Arthritis
LX6171 Low Dose
Age-Related Memory Disorders
Octreotide LAR Depot
Carcinoid Syndrome
LX1031 Low Dose
Irritable Bowel Syndrome
LX4211 High Dose
Type 2 Diabetes Mellitus
LX9211
Diabetic Peripheral Neuropathy
LX3305 mid dose
Rheumatoid Arthritis
LX4211 Low Dose
Type 2 Diabetes Mellitus
LX3305 low dose
Rheumatoid Arthritis
LX4211
Type 2 Diabetes Mellitus
LX1033
Irritable Bowel Syndrome
LX6171 High Dose
Age-Related Memory Disorders
LX7101
Primary Open-angle Glaucoma
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Telotristat etiprate | Phase 3 | Carcinoid Syndrome | - | - |
Oral Antidiabetes Drugs (OADs) | Phase 3 | Type 2 Diabetes Mellitus | - | - |
Insulin glargine (HOE901) | Phase 3 | Type 2 Diabetes Mellitus | - | - |
Sotagliflozin | Phase 3 | Type 2 Diabetes Mellitus | - | - |
Sulfonylurea | Phase 3 | Type 2 Diabetes Mellitus | - | - |
Sotagliflozin (SAR439954) | Phase 3 | Type 2 Diabetes Mellitus | - | - |
Glimepiride | Phase 3 | Type 2 Diabetes Mellitus | - | - |
LX1031 High Dose | Phase 2 | Irritable Bowel Syndrome | - | - |
LX9211 (blinded) | Phase 2 | Diabetic Peripheral Neuropathic Pain | - | - |
Volagidemab | Phase 2 | Type 1 Diabetes | - | - |
Telotristat Ethyl | Phase 2 | Locally Advanced Unresectable Pancreatic Adenocarcinoma | - | - |
LX3305 high dose | Phase 2 | Rheumatoid Arthritis | - | - |
LX6171 Low Dose | Phase 2 | Age-Related Memory Disorders | - | - |
Octreotide LAR Depot | Phase 2 | Carcinoid Syndrome | - | - |
LX1031 Low Dose | Phase 2 | Irritable Bowel Syndrome | - | - |
LX4211 High Dose | Phase 2 | Type 2 Diabetes Mellitus | - | - |
LX9211 | Phase 2 | Diabetic Peripheral Neuropathy | - | - |
LX3305 mid dose | Phase 2 | Rheumatoid Arthritis | - | - |
LX4211 Low Dose | Phase 2 | Type 2 Diabetes Mellitus | - | - |
LX3305 low dose | Phase 2 | Rheumatoid Arthritis | - | - |
LX4211 | Phase 2 | Type 2 Diabetes Mellitus | - | - |
LX1033 | Phase 2 | Irritable Bowel Syndrome | - | - |
LX6171 High Dose | Phase 2 | Age-Related Memory Disorders | - | - |
LX7101 | Phase 2 | Primary Open-angle Glaucoma | - | - |
Frequently asked questions
What is in LEXICON PHARMACEUTICALS, INC.'s drug pipeline?→
CatalystAlert tracks 24 drug candidates in LEXICON PHARMACEUTICALS, INC.'s (LXRX) pipeline across Phase 3, Phase 2. Its lead program is Sotagliflozin (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is LEXICON PHARMACEUTICALS, INC.'s next FDA catalyst?→
LEXICON PHARMACEUTICALS, INC.'s (LXRX) next tracked catalyst is a Phase 3 readout expected January 2027. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track LXRX biotech catalysts?→
Add LXRX to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow LEXICON PHARMACEUTICALS, INC.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.